


To whom it may concern

Vejle Sygehus
- en del af Sygehus Lillebælt
Onkologisk Afdeling
Kontakt: Lars Henrik Jensen
lars.henrik.jensen@rsyd.dk

10. August 2021

Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial
EudraCT nr. 2019-002071-34

The ALLOCATE study was approved by the regulatory authority, but for technical reasons we cancelled the study and it was never initiated.



Lars Henrik Jensen
Managing Consultant Oncologist
Assistant professor, PhD